Drug Profile
F 200
Alternative Names: EOS 200-F; Eos 200F; F-200; Ocular neovascularisation therapies - Protein Design LabsLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator PDL BioPharma
- Class Eye disorder therapies; Fab fragments
- Mechanism of Action Integrin alpha 5 beta 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Age-related macular degeneration
Most Recent Events
- 17 Mar 2005 Discontinued - Preclinical for Age-related macular degeneration in USA (Ophthalmic)
- 12 Oct 2004 Preclinical data from a media release have been added to the Eye Disorders pharmacodynamics section
- 23 Jul 2003 Data presented at the 94th Annual Meeting of the American Association for Cancer Research (AACR-2003) have been added to the pharmacodynamics section